Sickle Cell Disease Treatment Endari Soon to Be Available
Emmaus Medical has announced that Endari (L-glutamine oral powder) will be available starting the week of Dec 17th through the specialty pharmacy, U.S. Bioservices.
Endari was initially approved by the Food and Drug Administration (FDA) in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients ≥5 years. "Endari represents the first advancement in sickle cell treatment in nearly 20 years, and the first ever for children,” said Yutaka Niihara, MD, MPH, Chairman and Chief Executive Officer of Emmaus Life Sciences.
The mechanism of L-glutamine, an amino acid, in treating sickle cell disease is not fully understood. The pyridine nucleotides, NAD+ and its reduced form NADH, are involved in regulating and preventing oxidative damage in red blood cells. L-glutamine may improve the NAD redox potential in sickle red blood cells through increasing the availability of reduced glutathione.
Endari should be mixed immediately before ingestion in 8oz (240mL) of cold or room temperature beverage (eg, milk, water, apple juice) or 4–6oz of food (eg, applesauce, yogurt). It is supplied as 5g packets in 60-count cartons.
For more information call (877) 420-6493 or visit EndariRx.com.